UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial

Journal of clinical oncology, 2021-03, Vol.39 (8), p.920-930

2021

Volltextzugriff (PDF)

Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy

Blood, 2022-04, Vol.139 (14), p.2173-2185

2022

Volltextzugriff (PDF)

Safety and efficacy of tandem 131I-metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma

Pediatric blood & cancer, 2011-12, Vol.57 (7), p.1124-1129

2011

Volltextzugriff (PDF)

CAR T-Cell Therapy: Pediatric Patients With Relapsed and Refractory Acute Lymphoblastic Leukemia

Clinical journal of oncology nursing, 2017-04, Vol.21 (2 Suppl), p.22-28

2017

Volltextzugriff (PDF)

CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials

The Lancet. Haematology, 2021-10, Vol.8 (10), p.e711-e722

2021

Volltextzugriff (PDF)

Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy

Blood, 2023-02, Vol.141 (6), p.609-619

2023

Volltextzugriff (PDF)

Pediatric Survivorship: Considerations Following CAR T-Cell Therapy

Clinical Journal of Oncology Nursing, 2019-04, Vol.23 (2), p.35

2019

Volltextzugriff (PDF)

Implementation of an Automated Pediatric Malnutrition Screen Using Anthropometric Measurements in the Electronic Health Record

Journal of the Academy of Nutrition and Dietetics, 2019-08, Vol.119 (8), p.1243-1249

2019

Volltextzugriff (PDF)

Complete Versus Incomplete Hematologic Recovery after CAR T Cell Therapy: Implications for Relapse Free Survival and Overall Survival in Pediatric and Young Adult Patients with Relapsed/Refractory B-ALL

Blood, 2021-11, Vol.138 (Supplement 1), p.1747-1747

2021

Volltextzugriff (PDF)

CD22-Targeted CAR-Modified T-Cells Safely Induce Remissions in Children and Young Adults with Relapsed, CD19-Negative B-ALL after Treatment with CD19-Targeted CAR T-Cells

Blood, 2022-11, Vol.140 (Supplement 1), p.2376-2377

2022

Volltextzugriff (PDF)

Impact of socioeconomic status on survival after CD19 CART therapy

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.7013-7013

2022

Volltextzugriff (PDF)

Outcomes after Reinfusion of CD19-Specific Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Blood, 2021-11, Vol.138 (Supplement 1), p.474-474

2021

Volltextzugriff (PDF)

Cytogenetic Characteristics and Outcomes of Patients Receiving CTL019 CAR T Cell Therapy

Blood, 2019-11, Vol.134 (Supplement_1), p.1464-1464

2019

Volltextzugriff (PDF)

Cancer Immunotherapy: An Evidence-Based Overview and Implications for Practice

Clinical journal of oncology nursing, 2017-04, Vol.21 (2 Suppl), p.13-21

2017

Volltextzugriff (PDF)

Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia

Blood, 2018-11, Vol.132 (Supplement 1), p.556-556

2018

Volltextzugriff (PDF)

Effect of chimeric antigen receptor-modified T (CAR-T) cells on responses in children with non-CNS extramedullary relapse of CD19+ acute lymphoblastic leukemia (ALL)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.10507-10507

2017

Volltextzugriff (PDF)

The effect of pembrolizumab in combination with CD19-targeted chimeric antigen receptor (CAR) T cells in relapsed acute lymphoblastic leukemia (ALL)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.103-103

2017

Volltextzugriff (PDF)

Reinfusion of CD19 CAR T cells for relapse prevention and treatment in children with acute lymphoblastic leukemia

Blood advances, 2024-05, Vol.8 (9), p.2182-2192

2024

Volltextzugriff (PDF)

Immunotherapy Administration: Oncology Nursing Society Recommendations

Clinical journal of oncology nursing, 2017-04, Vol.21 (2 Suppl), p.5-7

2017

Volltextzugriff (PDF)

Safety and efficacy of tandem 131 I‐metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma

Pediatric blood & cancer, 2011-12, Vol.57 (7), p.1124-1129

2011

Volltextzugriff (PDF)

Risk-Adapted Preemptive Tocilizumab Decreases Severe Cytokine Release Syndrome (CRS) after CTL019 CD19-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Pediatric B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Biology of blood and marrow transplantation, 2020-03, Vol.26 (3), p.S39-S39

2020

Volltextzugriff (PDF)

1 – 24 von 24

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(20)

Publikationsform

Artikel
(24)

Sprache

Englisch
(24)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(12)
Life Sciences & Biomedicine
(11)
Science & Technology
(11)
Female
(8)
Male
(8)
Child
(7)
Oncology
(6)
Adolescent
(5)
Precursor Cell Lymphoblastic Leukemia-Lymphoma - Therapy
(5)
Recurrence
(5)
Adult
(4)
Child, Preschool
(4)
Hematology
(4)
Immunotherapy, Adoptive
(4)
Infant
(4)
Nursing
(4)
Young Adult
(4)
Antigens, Cd19 - Immunology
(3)
Precursor Cell Lymphoblastic Leukemia-Lymphoma - Drug Therapy
(3)
Receptors, Antigen, T-Cell - Therapeutic Use
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial

Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy

Safety and efficacy of tandem 131I-metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma

Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia

CAR T-Cell Therapy: Pediatric Patients With Relapsed and Refractory Acute Lymphoblastic Leukemia

CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials

Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy

Pediatric Survivorship: Considerations Following CAR T-Cell Therapy

Implementation of an Automated Pediatric Malnutrition Screen Using Anthropometric Measurements in the Electronic Health Record

Complete Versus Incomplete Hematologic Recovery after CAR T Cell Therapy: Implications for Relapse Free Survival and Overall Survival in Pediatric and Young Adult Patients with Relapsed/Refractory B-ALL

CD22-Targeted CAR-Modified T-Cells Safely Induce Remissions in Children and Young Adults with Relapsed, CD19-Negative B-ALL after Treatment with CD19-Targeted CAR T-Cells

Impact of socioeconomic status on survival after CD19 CART therapy

Outcomes after Reinfusion of CD19-Specific Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Cytogenetic Characteristics and Outcomes of Patients Receiving CTL019 CAR T Cell Therapy

Cancer Immunotherapy: An Evidence-Based Overview and Implications for Practice

Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia

Durable Remissions with Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in CAR-Naive and CAR-Exposed Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Effect of chimeric antigen receptor-modified T (CAR-T) cells on responses in children with non-CNS extramedullary relapse of CD19+ acute lymphoblastic leukemia (ALL)

The effect of pembrolizumab in combination with CD19-targeted chimeric antigen receptor (CAR) T cells in relapsed acute lymphoblastic leukemia (ALL)

Reinfusion of CD19 CAR T cells for relapse prevention and treatment in children with acute lymphoblastic leukemia

Immunotherapy Administration: Oncology Nursing Society Recommendations

Efficacy of Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Safety and efficacy of tandem 131 I‐metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma

Risk-Adapted Preemptive Tocilizumab Decreases Severe Cytokine Release Syndrome (CRS) after CTL019 CD19-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Pediatric B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Suchergebnisse filtern